Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MANBA | O00462 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344024 | 1.00 | LMNA (0.37) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL7529733 | 1.00 | LMNA (0.37) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL16883376 | 0.86 | — | — | |
| SCHEMBL12561444 | 0.86 | — | — | |
| SCHEMBL14477543 | 0.86 | — | — | |
| SCHEMBL2756249 | 0.85 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL1984099 | 0.85 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL18596140 | 0.85 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL2367932 | 0.85 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL6676888 | 0.85 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541161-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film using the same and pattern forming method | FUJIFILM CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120003586-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE SAME AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20120003586-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE SAME AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20110269071-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, CHEMICAL AMPLIFICATION RESIST COMPOSITION, AND RESIST FILM AND PATTERN FORMING METHOD USING THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-11-03 | — | — | US | disclosed |
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| EP-1472209-B1 | LIPOXIN A4 ANALOGS | BAYER SCHERING PHARMA AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-7435527-B2 | Mixture of acid generator and resin insoluble in alkaline developer and another acid decomposable compound | FUJIFILM CORPORATION (JP) | 2008-10-14 | — | — | US | disclosed |
| US-7435527-B2 | Mixture of acid generator and resin insoluble in alkaline developer and another acid decomposable compound | FUJIFILM CORPORATION (JP) | 2008-10-14 | — | — | US | disclosed |
| US-7235341-B2 | Positive resist composition | FUJIFILM CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-7235341-B2 | Positive resist composition | FUJIFILM CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTA4H | LMNA 761/4885CYP1A2 866/4885THPO 683/4885 |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTC4S | LMNA 725/4885CYP1A2 668/4885THPO 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.